Idarubicin

Template:Short description Template:Drugbox Idarubicin Template:IPAc-en or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts<ref name="Miller">Template:Cite journal</ref> itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Similar to other anthracyclines, it also induces histone eviction from chromatin.<ref name="Pang">Template:Cite journal</ref>

It belongs to the family of drugs called antitumor antibiotics.

It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia.<ref>Template:Cite journal</ref>

It is used for treatment of acute lymphoblastic leukemia and chronic myelogenous leukemia in blast crisis.<ref>Template:Cite book</ref>

It is distributed under the trade names Zavedos (UK) and Idamycin (USA).

Side effects

Diarrhea, stomach cramps, nausea and vomiting are common among patients treated with idarubicin.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

External links

• Idarubicin bound to proteins in the PDB

{{#invoke:Navbox|navbox}}